Current epidemiology and practice patterns in prevention and treatment of PD-related infections in Poland.


Journal

International urology and nephrology
ISSN: 1573-2584
Titre abrégé: Int Urol Nephrol
Pays: Netherlands
ID NLM: 0262521

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 14 10 2018
accepted: 10 12 2018
pubmed: 4 1 2019
medline: 8 6 2019
entrez: 4 1 2019
Statut: ppublish

Résumé

Peritoneal dialysis (PD) related infections are associated with technique failure and mortality. The aim of this multicentre study was to examine epidemiology, treatment and outcomes of PD-related infections in Poland as well as practice patterns for prevention of these complications in the context of current ISPD recommendations. A survey on PD practices in relation to infectious complications was conducted in 11 large Polish PD centres. Epidemiology of peritonitis and exit-site infections (ESI) was examined in all patients treated in these units over a 2 year period. The study included data on 559 PD patients with 62.4% on CAPD. Practice patterns for prevention of infectious complications are presented. The rate of peritonitis was 0.29 episodes per year at risk, with Gram positive microorganisms responsible for more than 50% of infections and 85.8% effectively treated. Diagnosis and treatment followed ISPD guidelines however most units did not provide an anti-fungal prophylaxis. Although neither of the centres reported routine topical mupirocin on catheter exit-site, the rate of ESI was low (0.1 episodes per year at risk), with Staphylococcus aureus as most common pathogen and full recovery in 78.3% of cases. The study shows rewarding outcomes in prevention and treatment of PD-associated infections, mainly due to a thorough compliance with the current ISPD guidelines, although some deviations from the recommendations in terms of practice patterns have been observed. More studies are needed in large numbers of patients to differentiate the importance of specific recommendations and further support the guidelines.

Sections du résumé

BACKGROUND BACKGROUND
Peritoneal dialysis (PD) related infections are associated with technique failure and mortality. The aim of this multicentre study was to examine epidemiology, treatment and outcomes of PD-related infections in Poland as well as practice patterns for prevention of these complications in the context of current ISPD recommendations.
METHODS METHODS
A survey on PD practices in relation to infectious complications was conducted in 11 large Polish PD centres. Epidemiology of peritonitis and exit-site infections (ESI) was examined in all patients treated in these units over a 2 year period.
RESULTS RESULTS
The study included data on 559 PD patients with 62.4% on CAPD. Practice patterns for prevention of infectious complications are presented. The rate of peritonitis was 0.29 episodes per year at risk, with Gram positive microorganisms responsible for more than 50% of infections and 85.8% effectively treated. Diagnosis and treatment followed ISPD guidelines however most units did not provide an anti-fungal prophylaxis. Although neither of the centres reported routine topical mupirocin on catheter exit-site, the rate of ESI was low (0.1 episodes per year at risk), with Staphylococcus aureus as most common pathogen and full recovery in 78.3% of cases.
CONCLUSION CONCLUSIONS
The study shows rewarding outcomes in prevention and treatment of PD-associated infections, mainly due to a thorough compliance with the current ISPD guidelines, although some deviations from the recommendations in terms of practice patterns have been observed. More studies are needed in large numbers of patients to differentiate the importance of specific recommendations and further support the guidelines.

Identifiants

pubmed: 30604230
doi: 10.1007/s11255-018-2057-9
pii: 10.1007/s11255-018-2057-9
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

335-341

Références

FEMS Immunol Med Microbiol. 1999 Dec;26(3-4):259-65
pubmed: 10575137
Am J Kidney Dis. 2000 Jun;35(6):1104-10
pubmed: 10845824
Perit Dial Int. 2000 May-Jun;20(3):352-3
pubmed: 10898060
Am J Kidney Dis. 2004 Oct;44(4):591-603
pubmed: 15384009
Am J Kidney Dis. 2005 Feb;45(2):372-80
pubmed: 15685516
Perit Dial Int. 2005 Jul-Aug;25(4):374-9
pubmed: 16022095
Nephrol Dial Transplant. 2005 Oct;20(10):2202-6
pubmed: 16046516
Perit Dial Int. 2006 Nov-Dec;26(6):625-32
pubmed: 17047225
Nephrology (Carlton). 2007 Jun;12(3):239-45
pubmed: 17498118
Nephrol Dial Transplant. 2007 Sep;22(9):2653-8
pubmed: 17517797
Perit Dial Int. 2009 May-Jun;29(3):330-9
pubmed: 19458307
Int J Infect Dis. 2010 Jun;14(6):e489-93
pubmed: 19926324
Perit Dial Int. 2010 Jul-Aug;30(4):440-7
pubmed: 20378843
J Bras Nefrol. 2010 Apr-Jun;32(2):156-64
pubmed: 21103675
Nephrol Dial Transplant. 1990;5(2):141-7
pubmed: 2113212
Nephrol Dial Transplant. 2011 Oct;26(10):3366-72
pubmed: 21382988
Perit Dial Int. 2011 Nov-Dec;31(6):651-62
pubmed: 21719685
Perit Dial Int. 2011 Nov-Dec;31(6):614-30
pubmed: 21880990
Nephrol Dial Transplant. 2012 Jun;27(6):2511-6
pubmed: 22189207
Perit Dial Int. 2016 May-Jun;36(3):297-307
pubmed: 26526049
Perit Dial Int. 2016 9-10;36(5):509-18
pubmed: 26764341
Nephrol Dial Transplant. 2016 Feb;31(2):214-22
pubmed: 26908816
Perit Dial Int. 2016 9-10;36(5):481-508
pubmed: 27282851
Perit Dial Int. 2017 Mar-Apr;37(2):170-176
pubmed: 27738087
Perit Dial Int. 2017 Mar-Apr;37(2):191-197
pubmed: 28096438
Perit Dial Int. 2017 May-Jun;37(3):266-272
pubmed: 28183858
Perit Dial Int. 2017 Mar-Apr;37(2):141-154
pubmed: 28360365
Nephrol Dial Transplant. 2017 Jun 1;32(6):1018-1023
pubmed: 28472525
Am J Kidney Dis. 2018 Jun;71(6):814-821
pubmed: 29289475
Perit Dial Int. 1994;14(1):48-51
pubmed: 8312414
Am J Kidney Dis. 1998 Mar;31(3):479-90
pubmed: 9506685
Perit Dial Int. 1998 May-Jun;18(3):261-70
pubmed: 9663889

Auteurs

Monika Lichodziejewska-Niemierko (M)

Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdańsk, Gdańsk, Poland. lichotek@gumed.edu.pl.
Dialysis Unit, Fresenius Nephrocare, Gdańsk, Poland. lichotek@gumed.edu.pl.

Michał Chmielewski (M)

Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdańsk, Gdańsk, Poland.

Ewa Wojtaszek (E)

Department of Nephrology, Dialysis and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.

Ewa Suchowierska (E)

1st Department of Nephrology and Transplantation with Dialysis Unit, Medical University of Białystok, Białystok, Poland.

Edyta Gołembiewska (E)

Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, Szczecin, Poland.

Magdalena Grajewska (M)

Department of Nephrology, Hypertension and Internal Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland.

Joanna Matuszkiewicz-Rowińska (J)

Department of Nephrology, Dialysis and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.

Beata Naumnik (B)

1st Department of Nephrology and Transplantation with Dialysis Unit, Medical University of Białystok, Białystok, Poland.

Beata Sulikowska (B)

Department of Nephrology, Hypertension and Internal Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland.

Stanisław Niemczyk (S)

Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine, Warsaw, Poland.

Renata Kłak (R)

Department of Nephrology and Transplantation Medicine, Wrocław Medical University, Wrocław, Poland.

Magdalena Mosakowska (M)

Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine, Warsaw, Poland.

Piotr Jagodziński (P)

Dialysis Unit, Fresenius Nephrocare, Gdańsk, Poland.

Bernadeta Marcykiewicz (B)

Dialysis Unit, Fresenius Nephrocare, Kraków, Poland.

Krzysztof Kalita (K)

Dialysis Unit, Fresenius Nephrocare, Sieradz, Poland.

Robert Krawczyk (R)

Dialysis Unit, Fresenius Nephrocare, Ostrów Wielkopolski, Poland.

Krzysztof Cieszyński (K)

Dialysis Unit, Fresenius Nephrocare, Ostrów Wielkopolski, Poland.

Mirosław Adamski (M)

Dialysis Unit, Fresenius Nephrocare, Zabrze, Poland.

Marek Bronk (M)

Clinical Microbiology Laboratory, University Hospital of Gdańsk, Gdańsk, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH